Pharma R&D: Lessons Learned for Future Growth Report presents a range of facts and figures, unique to the Pharmaprojects database, which clearly illustrates the nature and extent of the present crisis in pharma R&D. The versatility of the Pharmaprojects database has been used to seek information about trends and patterns in pharmaceutical product R&D that sheds light on the recent trend of decreasing numbers of newly approved therapeutic drugs facing the research-based pharmaceutical industry. These trends, along with their implications for the future of pharma R&D, are discussed in this report. The Report also suggests possible ways to tackle this crisis.
About the Author Paul Evers is a market research consultant and writer, specialising in the pharmaceutical and other healthcare industries. He has researched and written detailed studies on a wide range of pharmaceutical and medical market sectors including vaccines and immunotherapy; also on pharma regulatory topics and on strategic issues such as product lifecycle management. He studied medical sciences at the National University of Ireland and holds an honours degree in biological sciences and humanities from The Open University in the United Kingdom. The early years of his career were spent working as a writer in major pharma companies; during the 1980s he was Director of Marketing for Elan Corporation, based in Ireland.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
